Provided by Tiger Fintech (Singapore) Pte. Ltd.

GlycoMimetics

0.2637
+0.00411.58%
Post-market: 0.2430-0.0207-7.85%19:37 EDT
Volume:169.94K
Turnover:45.23K
Market Cap:17.01M
PE:-0.45
High:0.2730
Open:0.2670
Low:0.2630
Close:0.2596
Loading ...

Company Profile

Company Name:
GlycoMimetics
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
4
Office Location:
P.O. Box 65,Monrovia,Maryland,United States
Zip Code:
21770
Fax:
- -
Introduction:
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Directors

Name
Position
M. James Barrett
Chairman
Rachel K. King
Director, President and Chief Executive Officer
John L. Magnani
Director and Senior Vice President of Research
Daniel M. Junius
Director
Mark A. Goldberg
Director
Scott Koenig
Director
Timothy R. Pearson
Director

Shareholders

Name
Position
Rachel K. King
Director, President and Chief Executive Officer
Brian M. Hahn
Chief Financial Officer
Helen M. Thackray
Senior Vice President of Clinical Development and Chief Medical Officer
John L. Magnani
Director and Senior Vice President of Research